15 September 2020 - - US-based biopharmaceutical company Kronos Bio, Inc has appointed Elena Ridloff, CFA, to its board of directors, where she will serve as chair of the audit committee, the company said.

Ridloff brings nearly 20 years of experience in the biopharmaceutical sector, serving in senior leadership positions in corporate finance and investor relations, including a decade spent as an institutional investor covering the healthcare industry.

Ridloff currently serves as the executive vice president, chief financial officer for Acadia Pharmaceuticals Inc.

She joined the company in April 2018 as senior vice president, Investor Relations, where she led investor and financial communications activities.

Before joining ACADIA, Ridloff was vice president of Investor Relations at Alexion Pharmaceuticals and served as a member of the operating committee, where she built and led the investor relations function and played a key role in broadening and strengthening the shareholder base.

Prior to her role as an industry executive, Ridloff was responsible for investments in the biotechnology, pharmaceutical, medical device and life science sectors in her role as a managing director at Maverick Capital, a hedge fund based in New York.

She also was a senior analyst at Paramount Capital, an investment firm focused on the biotechnology sector. Ridloff also previously served as chief executive officer of Biovisio, an independent consulting firm serving the life sciences industry.

Ridloff earned her B.A. in history and sociology of science from the University of Pennsylvania. She is also a CFA charterholder.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription.